MMMartin Ian MacDonald

Martin Ian MacDonald

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martin Ian MacDonald has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Extrinsic airway compression: an unusual presentation of thoracic vertebral osteophytes from osteoarthritis

    by Afra Al Balushi, Martin Ian MacDonald, Brendon Friesen

    Extrinsic airway compression secondary to vertebral osteophytes is a rare clinical entity. We report a case of an elderly patient presenting with pneumonia where a subsequent chest CT scan showed right main bronchus compression caused by lower thoracic vertebral osteoarthritis-related osteophytes. There were additional incidental findings of sclerotic skeletal lesions prompting a new diagnosis of metastatic prostate cancer. The pneumonia improved with antibiotic therapy. Interventional management of airway compression was not pursued in this patient given his poor functional state and advanced metastatic malignancy. The patient was later readmitted with recurrent pneumonia as expected. Clinicians should be aware of this rare entity as a potential cause of airway compression identifiable on CT chest.

  • Open Access

    Asthma‐COPD overlap and asthma progressing to COPD: A complementary perspective

    by Christine F. McDonald, Philip G. Bardin, Martin MacDonald


  • Open Access

    Elevated blood lactate in COPD exacerbations associates with adverse clinical outcomes and signals excessive treatment with β2‐agonists

    by Martin I. MacDonald, Kevan R Polkinghorne, Chris J. MacDonald, Paul Leong, Kais Hamza, Gayan Kathriachchige, Christian Robert Osadnik, Paul T. King, Philip G. Bardin

    Background and Objective: Raised blood lactate secondary to high dose β2‐agonist treatment has been reported in asthma exacerbations but has not been investigated during acute exacerbations of COPD (AECOPD). We explored associations of blood lactate measurements with disease outcomes and β2‐agonist treatments during AECOPD.Methods: Retrospective (n = 199) and prospective studies (n = 142) of patients hospitalized with AECOPD were conducted. The retrospective cohort was identified via medical records and the prospective cohort was recruited during hospitalization for AECOPD. Baseline demographics, comorbidities, β2‐agonist treatment, biochemical measurements and clinical outcomes were compared between patients with normal (≤2.0 mmol/L) versus elevated lactate (>2.0 mmol/L). Regression analyses examined associations of lactate measurements with β2‐agonist dosages.Results: Demographic data and comorbidities were similar between high versus normal lactate groups in both cohorts. The populations were elderly (mean >70 years), predominantly male (>60%) with reduced FEV1 (%) 48.2 ± 19 (prospective cohort). Lactate was elevated in approximately 50% of patients during AECOPD and not related to evidence of sepsis. In the prospective cohort, patients with high lactate had more tachypnoea, tachycardia, acidosis and hyperglycaemia (p < 0.05) and received more non‐invasive ventilation (37% vs. 9.7%, p < 0.001, prospective cohort). There was a trend to longer hospitalization (6 vs. 5 days, p = 0.06, prospective cohort). Higher cumulative β2‐agonist dosages were linked to elevated lactate levels (OR 1.04, p = 0.01).Conclusion: Elevated lactate during AECOPD was common, unrelated to sepsis and correlated with high cumulative doses of β2‐agonists. Raised lactate may indicate excessive β2‐agonist treatment and should now be investigated as a possible biomarker.


  • Lessons from a failed randomized controlled trial of speech pathology intervention in vocal cord dysfunction

    by Joo Koh, Debra Phyland, Laurence Ruane, Adriana Avram, Elizabeth Leahy, Kenneth K. Lau, Martin MacDonald, Paul Leong, Malcolm Baxter, Philip G. Bardin


  • Open Access

    Cross-talk between IL-6 trans-signaling and AIM2 inflammasome/IL-1β axes bridge innate immunity and epithelial apoptosis to promote emphysema

    by Saleela M. Ruwanpura, Louise McLeod, Lovisa F. Dousha, Huei J. Seow, Alison C. West, Alice J. West, Teresa Weng, Mohammad Alanazi, Martin MacDonald, Paul T. King, et al.

    Pulmonary emphysema is associated with dysregulated innate immune responses that promote chronic pulmonary inflammation and alveolar apoptosis, culminating in lung destruction. However, the molecular regulators of innate immunity that promote emphysema are ill-defined. Here, we investigated whether innate immune inflammasome complexes, comprising the adaptor ASC, Caspase-1 and specific pattern recognition receptors (PRRs), promote the pathogenesis of emphysema. In the lungs of emphysematous patients, as well as spontaneous gp130 F/F and cigarette smoke (CS)-induced mouse models of emphysema, the expression (messenger RNA and protein) and activation of ASC, Caspase-1, and the inflammasome-associated PRR and DNA sensor AIM2 were up-regulated. AIM2 up-regulation in emphysema coincided with the biased production of the mature downstream inflammasome effector cytokine IL-1β but not IL-18. These observations were supported by the genetic blockade of ASC, AIM2, and the IL-1 receptor and therapy with AIM2 antagonistic suppressor oligonucleotides, which ameliorated emphysema in gp130 F/F mice by preventing elevated alveolar cell apoptosis. The functional requirement for AIM2 in driving apoptosis in the lung epithelium was independent of its expression in hematopoietic-derived immune cells and the recruitment of infiltrating immune cells in the lung. Genetic and inhibitor-based blockade of AIM2 also protected CS-exposed mice from pulmonary alveolar cell apoptosis. Intriguingly, IL-6 trans-signaling via the soluble IL-6 receptor, facilitated by elevated levels of IL-6, acted upstream of the AIM2 inflammasome to augment AIM2 expression in emphysema. Collectively, we reveal cross-talk between the AIM2 inflammasome/IL-1β and IL-6 trans-signaling axes for potential exploitation as a therapeutic strategy for emphysema.


  • Innovations during the Covid‐19 pandemic to maintain delivery of care for vocal cord dysfunction (VCD) in a multidisciplinary team (MDT) clinic

    by Joo Koh, Malcolm Baxter, Debra Phyland, Laurence Ruane, Adriana Avram, Elizabeth Leahy, Kenneth Lau, Martin MacDonald, Paul Leong, Philip Bardin

    See related Reply


  • Open Access

    Point of emission air filtration enhances protection of healthcare workers against skin contamination with virus aerosol

    by Shane A. Landry, Dinesh Subedi, Martin I. MacDonald, Samantha Dix, Donna M. Kutey, Jeremy J. Barr, Darren Mansfield, Garun S. Hamilton, Bradley A. Edwards, Simon A. Joosten

    See related Editorial


  • Right ventricular end‐diastolic volume and outcomes in exacerbations of COPD

    by Paul Leong, Christian R. Osadnik, Paul T. King, Martin I. MacDonald, Brian S. Ko, Kenneth K. Lau, Simon A. Joosten, Gayan Kathriachchige, Alexander Chua, Kais Hamza, et al.

    Background and objective Right ventricular (RV) volumes are crucial outcome determinants in pulmonary diseases. Little is known about the associations of RV volumes during hospitalized acute exacerbations of chronic obstructive pulmonary disease (AECOPD). We aimed to ascertain associations of RV end-diastolic volume indexed to body surface area (RVEDVI) during hospitalized AECOPD and its relationship with mortality in long-term follow-up. Methods This is a prospective observational cohort study (December 2013–November 2019, ACTRN12617001562369) using dynamic retrospective ECG-gated computed tomography during hospitalized AECOPD. RVEDVI was defined as normal or high using Framingham Offspring Cohort values. Cox regression determined the prognostic relevance of RVEDVI for death. Results A total of 148 participants (70 ± 10 years [mean ± SD], 88 [59%] men) were included, of whom 75 (51%) had high RVEDVI. This was associated with more frequent hospital admissions in the 12 months before admission (52/75 [69%] vs. 38/73 [52%], p = 0.04) and higher breathlessness (modified Medical Research Council score, 2.9 ± 1.3 vs. 2.4 ± 1.2, p = 0.007). During follow-up, high RVEDVI was associated with greater mortality (log-rank p = 0.001). In univariable Cox regression, increasing RVEDVI was associated with higher mortality (hazard ratio [HR]: 1.02 per ml/m2; 95% CI: 1.01, 1.03; p = 0.001). In multivariable Cox regression, RVEDVI was independently associated with mortality (HR: 1.01 per ml/m2; 95% CI: 1.00, 1.03; p = 0.050) at a borderline significance level. Adding RVEDVI to three COPD mortality prediction systems improved model fit (pooled chi-square test [BODE: p = 0.05, ADO: p = 0.04, DOSE: p = 0.02]). Conclusion In patients with hospitalized AECOPD, higher RV end-diastolic volume was associated with worse acute clinical parameters and greater mortality.


  • Open Access

    Personal protective equipment does not sufficiently protect against virus aerosol unless combined with advanced air purification or ventilation techniques

    by Shane A Landry, Dinesh Subedi, Jeremy J Barr, Martin I MacDonald, Samantha Dix, Donna M Kutey, Darren Mansfield, Garun S Hamilton, Bradley A. Edwards, Simon A Joosten

    Background: Healthcare workers (HCWs) are at risk from nosocomial transmission of SARS-CoV-2 from virus laden aerosols. This study aimed to: 1) quantify the degree of protection from virus aerosol provided by different types of mask (surgical, N95, fit-tested N95) and personal protective equipment (PPE); 2) determine if the use of a portable HEPA filter can enhance the effectiveness of PPE; 3) determine the effectiveness of a decontamination shower to remove virus aerosol contamination of a HCW. Methods: Virus aerosol exposure experiments were conducted using bacteriophage PhiX174 (10 8 copies/mL). A HCW wearing PPE (mask, gloves, gown, faceshield) was exposed to nebulised viruses for 40mins in a sealed clinical room. After exiting, the HCW doffed PPE. Virus exposure was quantified via skin swabs applied to the face and nostrils, forearms, neck, and forehead. Experiments were performed with and without the presence of a portable HEPA filter (set to 470m3/hr). Findings: Swabs quantified significant virus exposure under the surgical and N95 mask. Only the fit-tested N95 resulted in lower virus counts compared to no mask control (p=0.027). Nasal swabs demonstrated very high virus exposure, which was not mitigated by the surgical or N95 masks, although there was a trend for the fit-tested N95 mask to reduce virus counts (p=0.058). The addition of HEPA filtration substantially reduced virus counts from all swab sites, and to near zero levels when combined with a fit-tested N95 mask, gloves, gown and faces shield. Virus counts were substantially reduced to near zero levels following a shower. Interpretation: These data demonstrate that quantitatively fit tested N95 masks combined with a HEPA filter can offer protection against high virus aerosol loads at close range and for prolonged periods of time. Skin contamination from virus aerosol can be effectively by removed by showering. Funding: Epworth Hospital Capacity Building Research Grant ID: EH2020-654

  • Open Access

    Point of emission air filtration enhances protection of health care workers against skin contamination with virus aerosol

    by Shane Anthony Landry, Dinesh Subedi, Martin Ian MacDonald, Samantha Dix, Donna M Kutey, Jeremy J Barr, Darren Mansfield, Garun S Hamilton, Bradley A. Edwards, Simon Joosten

    Rationale We recently demonstrated that a patient hood with a high efficiency particulate air filter eliminates virus aerosol contamination when very large quantities of bacteriophage virus are aerosolised into a clinical room. While this containment method is relatively low cost, it is unclear whether similar efficacy can be achieved with lower cost/commercial grade air purifiers, or if such an approach protects healthcare workers against virus aerosol contamination. Method A total of 109 (10 ml of 108) PhiX174 bacteriophages was nebulized into a sealed clinical room. Surface contamination was detected by settle plates left uncovered during exposure. A healthcare worker remained in the room, personal exposure was determined by skin swabs after exiting the room, following doffing of personal protective equipment (PPE). Four skin areas were swabbed: forearms/hands, neck, forehead, under N95 mask. Three conditions were tested, 1) hood with hospital grade air purifier (IQ Air Health Pro 250), 2) hood with commercial air purifier (Philips 1000i), and 3) control (no hood/air-purification). Findings The control condition demonstrated extensive environmental and limited skin contamination underneath PPE, which was highest under an N95 mask. The commercial air purifier and hood provided environmental control of virus aerosol and almost zero skin contamination. In comparison, the hospital grade purifier provided complete environmental and skin contamination protection, despite a lower clean air filtration rate (240m3/hr vs 270m3/hr). Virus counts on plates and swabs were significantly lower for both air purifiers and across neck, forehead, and under the N95. There were no statistically significant differences in detected virus counts between air purifiers. Conclusion This cheap and scalable method may be an effective way to reduce the spread of COVID-19 in hospitals by enhancing the effectiveness of PPE worn by health care workers who care for COVID-19 patients and who are exposed to virus aerosol. Take home message Relatively cheap portable air purifiers combined with a hood dramatically reduce the spread of virus aerosol and protect against environmental and healthcare worker contamination. Plain Language Summary This study shows that commercially available air purifiers, when combined with a hood that covers the head of a clinical bed, effectively capture very large amounts of virus aerosol in a simulated hospital setting. This virus containment strategy strongly reduced the number of viruses landing on surfaces in a clinical room. Crucially, this strategy also reduced that amount of virus detected on a healthcare worker’s skin underneath personal protective equipment, including under an N95 respirator. This cheap and scalable method may be an effective way to reduce the spread of COVID-19 in hospitals by enhancing the effectiveness of personal protective equipment worn by health care workers who care for COVID-19 patients and who are exposed to virus aerosol.